{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:50:39Z","timestamp":1791888639897,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Cefepime, a broad spectrum antibiotic, is commonly prescribed in intensive care units (ICU) and may be an overlooked cause of neurologic symptoms such as encephalopathy, myoclonus, seizures, and coma. We aimed to characterize cefepime neurotoxicity in the ICU.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We performed a retrospective study of adult ICU patients treated with intravenous cefepime for at least 3 days between January 1, 2009 and December 31, 2011. The primary outcome was the development of cefepime neurotoxicity, with the likelihood of causality ascribed via a modified Delphi method.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>This study included 100 patients. The mean age was 65.8 years (\u00b1 12.7 years). The median daily average dose of cefepime was 2.5 (IQR 2.0 to 3.5) grams. The median treatment duration was 6 (IQR 4 to 10) days. Renal failure in any form was present in 84 patients. Chronic kidney disease affected 40 patients, and 77 had acute kidney injury. Cefepime neurotoxicity occurred in 15 patients. Of these, seven were considered definite cases, three probable, and five possible. Neurotoxic symptoms included impaired consciousness (n\u2009=\u200913), myoclonus (n\u2009=\u200911), disorientation (n\u2009=\u20096), and nonconvulsive status epilepticus (n\u2009=\u20091). The dose of cefepime was appropriately adjusted for renal clearance in 64 patients (75.3%) without cefepime neurotoxicity and four patients (28.6%) with neurotoxicity (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Chronic kidney disease was present in 30 patients (35.3%) without neurotoxicity and in 10 (66.7%) of those with neurotoxicity (<jats:italic>P<\/jats:italic>\u2009=\u20090.04).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Critically ill patients with chronic kidney disease are particularly susceptible to cefepime neurotoxicity. Myoclonus and impaired consciousness are the predominant clinical manifestations. Neurotoxic symptoms occur more often when the cefepime dose is not adjusted for renal function, but can still occur despite those modifications.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc13094","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T16:02:40Z","timestamp":1383840160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy"],"prefix":"10.1186","volume":"17","author":[{"given":"Jennifer E","family":"Fugate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaaz A","family":"Kalimullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Hocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelco FM","family":"Wijdicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A","family":"Rabinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,7]]},"reference":[{"key":"3038_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/clpt.1990.149","volume":"48","author":"RH Barbhaiya","year":"1990","unstructured":"Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA: Pharmacokinetics of cefepime in subjects with renal insufficiency.\n                           Clin Pharmacol Ther 1990, 48: 268-276. 10.1038\/clpt.1990.149","journal-title":"Clin Pharmacol Ther"},{"key":"3038_CR2","first-page":"312","volume":"14","author":"NL Smith","year":"2012","unstructured":"Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J: Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime.\n                           Crit Care Resusc 2012, 14: 312-315.","journal-title":"Crit Care Resusc"},{"key":"3038_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/jac\/dkn256","volume":"62","author":"J Bresson","year":"2008","unstructured":"Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S: Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltration.\n                           J Antimicrob Chemother 2008, 62: 849-850. 10.1093\/jac\/dkn256","journal-title":"J Antimicrob Chemother"},{"key":"3038_CR4","first-page":"65","volume":"2005","author":"FJ Capparelli","year":"1840","unstructured":"Capparelli FJ, Diaz MF, Hlavnika A, Wainsztein NA, Leiguarda R, Del Castillo ME: Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.\n                           Neurology 1840, 2005: 65.","journal-title":"Neurology"},{"key":"3038_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00134-001-1170-9","volume":"28","author":"D Chatellier","year":"2002","unstructured":"Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F: Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure.\n                           Intensive Care Med 2002, 28: 214-217. 10.1007\/s00134-001-1170-9","journal-title":"Intensive Care Med"},{"key":"3038_CR6","first-page":"526","volume":"21","author":"EO Garces","year":"2008","unstructured":"Garces EO, de Azambuja MFA, da Silva D, Bragatti JA, Jacoby T, Thome FS: Renal failure is a risk factor for cefepime-induced encephalopathy.\n                           J Nephrol 2008, 21: 526-534.","journal-title":"J Nephrol"},{"key":"3038_CR7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1345\/aph.1L307","volume":"42","author":"MF Grill","year":"2008","unstructured":"Grill MF, Maganti R: Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring.\n                           Ann Pharmacother 2008, 42: 1843-1850. 10.1345\/aph.1L307","journal-title":"Ann Pharmacother"},{"key":"3038_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0987-7053(00)00234-3","volume":"30","author":"P Jallon","year":"2000","unstructured":"Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A, Picard F, Hefft S, Assal F: Severe but reversible encephalopathy associated with cefepime.\n                           Neurophysiol Clin 2000, 30: 383-386. 10.1016\/S0987-7053(00)00234-3","journal-title":"Neurophysiol Clin"},{"key":"3038_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1592\/phco.26.8.1169","volume":"26","author":"S Lam","year":"2006","unstructured":"Lam S, Gomolin IH: Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.\n                           Pharmacotherapy 2006, 26: 1169-1174. 10.1592\/phco.26.8.1169","journal-title":"Pharmacotherapy"},{"key":"3038_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.yebeh.2005.09.010","volume":"8","author":"R Maganti","year":"2006","unstructured":"Maganti R, Jolin D, Rishi D, Biswas A: Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function.\n                           Epilepsy Behav 2006, 8: 312-314. 10.1016\/j.yebeh.2005.09.010","journal-title":"Epilepsy Behav"},{"key":"3038_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/sj.bmt.1704314","volume":"33","author":"E Plensa","year":"2004","unstructured":"Plensa E, Gallardo E, Ribera JM, Batlle M, Oriol A, Costa J: Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation.\n                           Bone Marrow Transplant 2004, 33: 119-120. 10.1038\/sj.bmt.1704314","journal-title":"Bone Marrow Transplant"},{"key":"3038_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ndt\/gfm713","volume":"23","author":"J Sonck","year":"2008","unstructured":"Sonck J, Laureys G, Verbeelen D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure.\n                           Nephrol Dial Transplant 2008, 23: 966-970.","journal-title":"Nephrol Dial Transplant"},{"key":"3038_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","volume":"41","author":"J Barr","year":"2013","unstructured":"Barr J, Fraser GL, Puntillo K, Ely EW, G\u00e9linas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the Intensive Care Unit.\n                           Crit Care Med 2013, 41: 263-306.","journal-title":"Crit Care Med"},{"key":"3038_CR14","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/cc6149","volume":"3","author":"TD Girard","year":"2008","unstructured":"Girard TD, Pandharipande PP, Ely EW: Delirium in the intensive care unit.\n                           Crit Care Suppl 2008, 3: S3.","journal-title":"Crit Care Suppl"},{"key":"3038_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7326\/0003-4819-101-1-92","volume":"101","author":"SR Snavely","year":"1984","unstructured":"Snavely SR, Hodges GR: The neurotoxicity of antibacterial agents.\n                           Ann Intern Med 1984, 101: 92-104. 10.7326\/0003-4819-101-1-92","journal-title":"Ann Intern Med"},{"key":"3038_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ncl.2011.07.003","volume":"29","author":"S Hocker","year":"2011","unstructured":"Hocker S, Rabinstein AA: A clinical and investigative approach to the patient with diminished responsiveness.\n                           Neurol Clin 2011, 29: 739-747. 10.1016\/j.ncl.2011.07.003","journal-title":"Neurol Clin"},{"key":"3038_CR17","unstructured":"FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients not Receiving Dosage Adjustments for Kidney Impairment. Available at: . Accessed April 26, 2013 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm309661.htm Available at: . Accessed April 26, 2013"},{"key":"3038_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/archneurol.2011.204","volume":"68","author":"G Naeije","year":"2011","unstructured":"Naeije G, Lorent S, Vincent JL, Legros B: Continuous epileptiform discharges in patients treated with cefepime or meropenem.\n                           Arch Neurol 2011, 68: 1303-1307. 10.1001\/archneurol.2011.204","journal-title":"Arch Neurol"},{"key":"3038_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3109\/00365548.2011.581308","volume":"43","author":"VG Gangireddy","year":"2011","unstructured":"Gangireddy VG, Mitchell LC, Coleman T: Cefepime neurotoxicity despite renal adjusted dosing.\n                           Scand J Infect Dis 2011, 43: 827-829. 10.3109\/00365548.2011.581308","journal-title":"Scand J Infect Dis"},{"key":"3038_CR20","first-page":"1026","volume":"22","author":"M Yadla","year":"2011","unstructured":"Yadla M, Kishore CK, Sriramnaveen P, Reddy YS, Sainaresh VV, Bhuma V, Sivakumar V: Neurotoxicity due to cefepime in patients on maintenance hemodialysis.\n                           Saudi J Kidney Dis Transpl 2011, 22: 1026-1027.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"3038_CR21","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1186\/cc8941","volume":"14","author":"TM Chapuis","year":"2010","unstructured":"Chapuis TM, Giannoni E, Majcherczyk PA, Chiol\u00e9ro R, Schaller MD, Berger MM, Bolay S, D\u00e9costerd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients.\n                           Crit Care 2010, 14: R51. 10.1186\/cc8941","journal-title":"Crit Care"},{"key":"3038_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/jac\/dks012","volume":"67","author":"C Durand-Maugard","year":"2012","unstructured":"Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, Hary L, Maizel J, Prud'homme-Bernardy A, Andr\u00e9jak C, Andr\u00e9jak M: Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports.\n                           J Antimicrob Chemother 2012, 67: 1297-1299. 10.1093\/jac\/dks012","journal-title":"J Antimicrob Chemother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc13094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc13094\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc13094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:51:59Z","timestamp":1728384719000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc13094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,7]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1186\/cc13094","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,7]]},"assertion":[{"value":"26 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R264"}}